Filing Flows › Castle Biosciences (CSTL) › Q2 2026 › vs Q1 2026
Castle Biosciences (CSTL) Q2 2026 vs Q1 2026 (quarter over quarter)
Castle Biosciences's revenue rose $19.9M (+24%) from $83.7M in Q1 2026 to $104M in Q2 2026. The biggest changes: Non-Dermatologic +$12.3M (+29%); Dermatologic +$7.6M (+18%).
Castle Biosciences, Q2 2026: revenue $104M (+20% year over year), operating margin -3.0%, net loss $2.1M, operating cash flow $15.2M. The chart draws each line against Q1 2026, the increases inside each band.
Margins
| Q2 2026 | Q1 2026 | Change | |
|---|---|---|---|
| Free cash flow margin | 6.3% | -41.3% | +47.7 pts |
Every line
| Line | Q2 2026 | Q1 2026 | Change | % |
|---|---|---|---|---|
| Non-Dermatologic | $54.8M | $42.6M | $12.3M | +29% |
| Dermatologic | $48.7M | $41.1M | $7.6M | +18% |
| Revenue | $104M | $83.7M | $19.9M | +24% |
| Other income, net | $1.4M | $4.0M | −$2.6M | -65% |
| Net loss | $2.1M | $14.5M | −$12.5M | -86% |
| Costs & expenses | $107M | $102M | $4.8M | +5% |
| Operating costs | $107M | $102M | $4.5M | +4% |
| Income tax | $370K | $109K | $261K | +239% |
| Cost of revenue | $23.7M | $20.5M | $3.2M | +15% |
| Research & development | $14.5M | $14.4M | $115K | +0.8% |
| SG&A | $66.1M | $64.9M | $1.2M | +2% |
| Other operating costs | $2.3M | $2.2M | $25K | +1% |
| Operating cash sources | $17.3M | −$7.6M | $24.9M | — |
| Depreciation & amortization | $4.1M | $3.9M | $141K | +4% |
| Share-based compensation | $11.6M | $9.8M | $1.8M | +19% |
| Working capital & other | $1.6M | −$21.3M | $22.9M | — |
| Net loss absorbed | $2.1M | $14.5M | −$12.5M | -86% |
| Operating cash flow | $15.2M | −$22.1M | $37.3M | — |
| Free cash flow (OCF − capex) | $6.6M | −$34.6M | $41.1M | — |
| Capital expenditures | $8.7M | $12.5M | −$3.8M | -31% |
Questions
How much did Castle Biosciences's revenue grow quarter over quarter in Q2 2026?
Castle Biosciences's revenue rose $19.9M (+24%) from $83.7M in Q1 2026 to $104M in Q2 2026.
What drove Castle Biosciences's revenue change in Q2 2026?
Non-Dermatologic +$12.3M (+29%); Dermatologic +$7.6M (+18%).